Now Part of Sartorius

Adding Talent & Technologies

Sartorius has leading market positions in core technologies and is continuously expanding its portfolio by new, complementary technologies that help our biopharma customers develop and manufacture medications faster and more easily. Integrating innovations through acquisitions is one of the pillars of our innovative power and part of our growth strategy.

In recent years, Sartorius has been continuously making acquisitions, including:

Solutions for production of cell & gene therapies and vaccines
Systems for cell and protein analysis
Chromatography and tangential flow filtration systems
Cell culture media
Bioprocessing software

Acquisitions

10

Closed Since 2020

Employees

~1,200

Welcomed Since 2020

Production Sites

16

Added to Network Since 2020

Explore Our Recent Acquisitions

July 2025: Mattek

MatTek is a leading developer and manufacturer of human cell-based microtissues and 3D models that accelerate drug development.

July 2023: Polyplus

Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale.

2022: Albumedix

Recombinant human albumin by Albudemix is required for applications like cell culture media, vaccines & viral therapies.

2022: Chromatography Assets from Novasep

The unit comprises resin-based batch and intensified chromatography systems, primarily for smaller molecules.

Cell Selection and Retrieval instrument

2022: ALS Automated Lab Solutions (Majority)

ALS develops, manufactures and markets solutions for the automated analysis, selection and isolation of cells.

2021: Xell AG

Xell develops and produces media and feed supplements for cell cultures, especially for manufacturing viral vectors.

2021: CellGenix (Majority)

CellGenix produces and markets cell culture components, such as growth factors, cytokines and media in GMP quality.

2020: WaterSep BioSeparations

WaterSep BioSeparations develops and manufactures hollow‑fiber membrane devices and pre-sterilized assemblies.

2020: BIA Separations

BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules.

2020: Danaher (Selected Businesses)

FortéBio business for label-free biomolecular characterization, and chromatography systems and resins business.

Proven Track Record with Acquisitions

More Information for Investors

Newsroom

Careers

Investors